TY - JOUR T1 - Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P3438 AU - Rain Jõgi AU - Kaja Julge AU - Priit Samarüütel AU - Liisa Raatikainen AU - Timo Vanto Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P3438.abstract N2 - Dry powder inhalers (DPIs) are inspiratory flow driven. We sought to characterise inspiratory flow parameters of placebo dry powder inhaler devices in asthma patients of various age groups and in patients with chronic obstructive pulmonary disease (COPD) in an open, randomised, multicentre study (SALIF). Preliminary data of the Easyhaler® arm will be presented.The primary variable was the peak inspiratory flow (PIF) rate through the inhaler. Three inspiratory flow curves were recorded and the best of them was analysed. To ensure consistent dose delivery of the drug peak inspiratory flow rates for this device should be 28 L/min or higher.A total of 227 subjects with documented diagnosis of asthma and/or COPD of various severities were included in the open-label study. Asthmatic patients were divided into three different age groups: 4-11 years (n=60), 12-64 years (n=62) and ≥ 65 years (n=52). COPD patients consisted of all ages groups (n=53)View this table:Descriptive statistics of PIF values in different subgroupsIrrespective of age or the severity of disease, most asthma and COPD patients were able to inhale through the studied DPI device with an adequate PIF. ER -